Clinical trial
Treatment of Behavioral Symptoms in Alzheimer's Disease
NCT00009217 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00009217 |
|---|---|
| Title | Treatment of Behavioral Symptoms in Alzheimer's Disease |
| Official title | Treatment of Behavioral Symptoms in Alzheimer's Disease |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Psychosis, Agitation |
| Intervention type | Drug |
| Interventions | Haloperidol-Haloperidol, Haloperidol-Placebo |
| Enrollment | 44 |
| Start date | Jan 1, 1999 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jan 24, 2001 |
| Last update posted | May 24, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: